The next generation of therapies, whether small molecule, biological, or cell/tissue based, depend on quantitative imaging assays for development. In the case of small molecules, peptides, and antibody-based treatments these assays streamline the development process by providing relevant mechanistic insights earlier in the discovery process and eliminating surprises in the clinic. In the case of cell and tissue therapies, quantitative imaging goes beyond development and is essential for quality control, including identity testing, lot release, and batch monitoring. To support these applications, Nikon has developed advanced imaging devices and software driven by artificial intelligence and machine-learning image-analysis algorithms.
Nikon BioImaging Lab is a state-of-the-art facility located in Cambridge, Massachusetts, that provides these advanced technologies to support the burgeoning regenerative medicine and biotech sector. At Nikon BioImaging Lab, Nikon offers the expertise and equipment required to carry out simple to complex cell-based imaging assays. Customers can choose from a menu of ready-made assays or can work with Nikon application scientists to implement custom assays. The facility is equipped to handle the complete assay process—cell thawing, expansion, differentiation, drug and toxicology screening, image data acquisition, and image data analysis.